Conference & Events
Event Details
4th RSC/SCI symposium on GPCRs in Medicinal Chemistry
G-protein-coupled receptors (GPCRs) play a crucial role in transmitting chemical signals across cell membranes and converting them into cellular responses. As such, they are involved in many diseases and continue to represent the target of a large proportion of all modern medicinal drugs. Building on the success of the previous three meetings, the next meeting in this series will be supported by Lilly UK.
Date: 17 September 2012 09:00 - 19 September 2012 12:30
Event Subject(s):
Biosciences
Industry & Technology
Venue
Lilly UK
Warwick Room
Conference Centre
Erl Wood Manor
Windlesham
GU20 6PH
United Kingdom
Find this location using Google Map
Useful link:
https://www.lilly.co.uk/FINALLillyErlWoodMapA4.pdf
RSC Organiser Information
Biological and Medicinal Chemistry Sector
Jointly organised with: SCI's Fine Chemicals Group
Sponsored by: Lilly
Contact for Event Information
Name : Mrs Maggi Churchouse
Address:
Maggi Churchouse Events
3 East Barn
Market Weston Road, Thelnetham
Diss
IP22 1JJ
United Kingdom
Tel:
+44 (0)1359 221004
Fax:
+44 (0)1359 221004
Email:
maggi@maggichurchouseevents.co.uk
Contact Useful link:
www.maggichurchouseevents.co.uk/bmcs
Additional Information
Speaker Information:
Monday, 17th September
09:00 Registration and refreshments
09:55 Opening remarks
10:10 mGlu4 PAMs for the Treatment of Parkinson’s Disease
Craig Lindsley, Vanderbilt University
10:55 A drug discovery journey within novel positive allosteric modulators of Class C GPCRs
Sylvain Célanire, Addex Pharmaceuticals
11:35 Lead optimisation with GPCR models
Christofer Tauterman, Boehringer Ingelheim
12:15 Lunch
13:15 Biophysical screening and multi-target design for GPCR drug discovery
Andrew Hopkins, University of Dundee
13:55 The discovery of orally administered Bradykinin B1 antagonists and the emergence of predictive homology models
James Madden, Evotec
14:35 GPCR fragment and structure based drug discovery
John Christopher, Heptares
15:15 Refreshments
15:45 Discovery of orexin antagonists for the treatment of sleep disorders
Paul Coleman, Merck
16:20 Intranasally and orally administered CGRP (calcitonin gene-related peptide) receptor antagonists for the treatment of migraine: discovery and development
John Macor, BMS
17:00 Close
Tuesday, 18th September
09:05 Potent and selective, orally active GPBAR1 agonists as chemical biology probes
Patrizio Mattei, F Hoffmann-La Roche AG
09:45 Discovery of novel CRTh2 receptor antagonists for treatment of allergic diseases
David Sandham, Novartis
10:25 Refreshments
10:55 Adventures in the discovery and development of a GPR119 agonist
Paul Feldman, GlaxoSmithKline
11:35 Discovery of APD811: an orally available prostacyclin receptor agonist for the treatment of Pulmonary Arterial Hypertension (PAH)
Graeme Semple, Arena
12:15 Lunch
13:15 Novel mGlu5 antagonists for Parkinson's disease
Magnus Walter, Lilly
13:55 Discovery of novel, negative allosteric modulators of mGlu5 for treatment of GERD
Kenneth Granberg, AstraZeneca
14:35 Amido-1,2,3-thiadiazole derivatives as novel S1P1 selective agonists
Nuria Aguilar, Almirall
15:15 Refreshments
15:45 A journey around H3 inverse agonists: the discovery of UCB2892
Laurent Provins, UCB
16:20 The design of pyrimidino-azepines as potent, subtype selective 5-HT2C partial agonists
Ian Storer, Pfizer
17:00 Poster and exhibition session with aperitif
19:30 Gala dinner
Wednesday, 19th September
09:00 Structural insights into the dynamic process of GPCR activation
Brian Kobilka, Stanford University
09:45 New perspectives on druggability and SBDD from GPCR structures
Jon Mason, Heptares
10:25 Refreshments
10:55 Drug design for G-protein-coupled receptors by a ligand-based NMR method
Peter Monecke, Sanofi
11:35 Glucagon receptor antagonists: from the laboratory to the patient
Phil Hipskind, Lilly US
12:15 Closing remarks and depart
Booking form or other file(s):
GPCRs - final announcement.pdf
Useful link:
www.maggichurchouseevents.co.uk/bmcs
Additional categories:
Events for the Public
Access: Public Event
Ticket/Registration Information:
Registration is now open.
Card payment: please register online via www.maggichurchouseevents.co.uk/bmcs.
Cheque and bank transfer payment: please complete and return the registration form (found online).
Charges: please refer to the registration form or the online payment page.
Discounts: We offer discounts to RSC and SCI members and student members who
quote their membership number. Early-bird discounts apply to payments received by
2nd July. A late fee of £50 will be charged on registration payments received after 8th
August.
Accommodation:
The conference hotel is the Hilton Bracknell Hotel, Bagshot Road, Bracknell, RG12 0QJ. A preferential rate has been secured, namely £109 per double room per night for single occupancy, including breakfast and VAT. Although this booking system is not yet open, bookings will be made:
by telephone 01256 316975 (0800-1800 hrs Monday to Friday) or 0800 856 8000 outside these hours
by e-mail laura.brooks@hilton.com
online www.hilton.co.uk/bracknell, go to Check Availability at the top of the page, and add the dates. Then insert the reference code AGPCR under Group Code on the righthand side.
Remember to quote the reference “AGPCR” to obtain this rate, which is available until 17th August only.
Other information:
Posters are invited for display throughout the meeting and for presentation on Tuesday, 18th September. Please download a template and send a one-page abstract to the secretariat by 30th July.
Features of the Meeting
Two-and-a-half-day conference programme covering: new technologies in GPCR research, GPCR activation, lead generation approaches, GPCR peptide receptors, allosteric modulation of GPCRs, and structural biology and drug design
- Plenary speakers, including Craig Lindsley (Vanderbilt University), Brian Kobilka (Stanford University), and Andrew Hopkins (University of Dundee)
- Medicinal chemistry case studies from leading industrial scientists
- Evening networking reception
- Poster session
- Gala dinner
- Trade exhibition opportunities
